Performance has declined for three consecutive
Posted: Thu Feb 13, 2025 4:24 am
Dai Lizhong, Chairman of Shengxiang Bio, said that efficient integration and personalization of prevention, diagnosis and treatment is the inevitable trend of proactive health, and is also the direction of Shengxiang Bio's innovation and exploration in the new era of life science.
The strong alliance between Shengxiang Bio and Zhongshan Haiji will leverage the resource advantages of precision diagnosis and biomanufacturing, which will help create an integrated health solution for pediatric diagnosis and treatment.
Before this merger and acquisition , Shengxiang Bio 's attributable net profit had declined for three consecutive years from 2021 to 2023 .
Data shows that from 2020 to 2023, Shengxiang Bio achieved job seekers data revenues of 4.763 billion yuan, 4.515 billion yuan, 6.45 billion yuan and 1.007 billion yuan, respectively; among which the full-year operating income in 2023 showed a sharp decline; from 2020 to 2023, the company 's attributable net profits were 2.617 billion yuan, 2.243 billion yuan, 1.937 billion yuan and 364 million yuan, respectively.
In the first three quarters of 2024, Shengxiang Bio's attributable net profit also declined. During the reporting period, the company achieved operating income of 1.033 billion yuan, a year-on-year increase of 63.24%; the corresponding attributable net profit was 195 million yuan, a year-on-year decrease of 34.8%.
In order to reduce its dependence on the sales of new coronavirus nucleic acid testing reagents and instruments , in 2022, Shengxiang Bio proposed "second entrepreneurship" to find new growth points.
On May 9, 2023, the company announced that it plans to jointly invest with its related parties to establish Hunan Shengxiang Ansai Biotechnology Co., Ltd. to further improve the company's comprehensive strategic layout in the field of immunodiagnosis, especially chemiluminescence.
A year later, Shengxiang Bio announced again that it plans to jointly invest with its related parties in a joint venture, Hunan Shengwei Sumin Biotechnology Co., Ltd., to further focus on the field of rapid drug sensitivity testing.
The strong alliance between Shengxiang Bio and Zhongshan Haiji will leverage the resource advantages of precision diagnosis and biomanufacturing, which will help create an integrated health solution for pediatric diagnosis and treatment.
Before this merger and acquisition , Shengxiang Bio 's attributable net profit had declined for three consecutive years from 2021 to 2023 .
Data shows that from 2020 to 2023, Shengxiang Bio achieved job seekers data revenues of 4.763 billion yuan, 4.515 billion yuan, 6.45 billion yuan and 1.007 billion yuan, respectively; among which the full-year operating income in 2023 showed a sharp decline; from 2020 to 2023, the company 's attributable net profits were 2.617 billion yuan, 2.243 billion yuan, 1.937 billion yuan and 364 million yuan, respectively.
In the first three quarters of 2024, Shengxiang Bio's attributable net profit also declined. During the reporting period, the company achieved operating income of 1.033 billion yuan, a year-on-year increase of 63.24%; the corresponding attributable net profit was 195 million yuan, a year-on-year decrease of 34.8%.
In order to reduce its dependence on the sales of new coronavirus nucleic acid testing reagents and instruments , in 2022, Shengxiang Bio proposed "second entrepreneurship" to find new growth points.
On May 9, 2023, the company announced that it plans to jointly invest with its related parties to establish Hunan Shengxiang Ansai Biotechnology Co., Ltd. to further improve the company's comprehensive strategic layout in the field of immunodiagnosis, especially chemiluminescence.
A year later, Shengxiang Bio announced again that it plans to jointly invest with its related parties in a joint venture, Hunan Shengwei Sumin Biotechnology Co., Ltd., to further focus on the field of rapid drug sensitivity testing.